Company intelligence / Profile preview

GlycoGen

Alachua, Florida, USA

Ownership: Private
Development stage: Other

Overview

GlycoGen Inc. was a biotechnology company focused on the discovery and development of carbohydrate-based therapeutics and diagnostics. The company specialized in glycobiology, specifically targeting selectins and other carbohydrate-binding proteins involved in inflammatory processes and cancer metastasis. Its core technology platform enabled the design of small molecule mimetics of complex carbohydrates to treat conditions such as asthma, psoriasis, and reperfusion injury. GlycoGen was acquired by Alexion Pharmaceuticals in 2000 to bolster Alexion's portfolio of anti-inflammatory and cardiovascular treatments.

Therapeutic areas: ImmunologyCardiovascularDermatologyPulmonologyOncology
Modalities: Small moleculeCarbohydrate-based therapeutics
Industry: Biotech

Partnerships

Alexion Pharmaceuticals

Beyond the preview

Go deeper on GlycoGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoGen.

Explore the full profile